Form 4: Humacyte CEO Niklason Granted 311,100 Stock Options

Humacyte's President and CEO, Laura E. Niklason, was granted 311,100 stock options with an exercise price of $1.23, vesting over three years.

Summary

• Laura E. Niklason, President, CEO, and Director of Humacyte, Inc. (HUMA), acquired 311,100 stock options.
• The transaction date for the option grant was November 16, 2025.
• Each option has an exercise price of $1.23.
• The options are for Common Stock and expire on November 16, 2035.
• The options vest in three tranches: the first 1/3 becomes exercisable on February 14, 2026, the second 1/3 on November 16, 2026, and the final 1/3 on November 16, 2027.
• Following this transaction, Laura E. Niklason beneficially owns 311,100 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally a positive signal, indicating management's continued commitment and alignment with shareholder interests. It's a standard compensation practice that incentivizes long-term performance.

Positives

• The grant of stock options to the President and CEO aligns management's long-term interests with those of shareholders, incentivizing performance and stock price appreciation.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Future Outlook

The vesting schedule for the granted stock options indicates a multi-year incentive structure, aligning the CEO's compensation with future company performance through November 2027.

Industry Context

This Form 4 filing reflects a standard executive compensation practice within the biotechnology and healthcare sectors, where stock options are commonly used to attract, retain, and incentivize key leadership by linking their financial success to the company's long-term share price performance.

Comparison to Industry Standards

• The grant of stock options to a CEO is a common practice in publicly traded companies, particularly in growth-oriented sectors like biotechnology, aligning executive incentives with shareholder value creation.
• The vesting schedule over multiple years is typical for long-term incentive plans, similar to those observed at comparable biotech firms such as Organogenesis Holdings Inc. (ORGO) or MiMedx Group, Inc. (MDXG) for their executive teams.

Stakeholder Impact

• Shareholders: The option grant aims to align the CEO's financial incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• The stock options will become exercisable in three tranches on February 14, 2026, November 16, 2026, and November 16, 2027.

Key Dates

Keywords

Humacyte, HUMA, Stock Options, Insider Transaction, Form 4, Executive Compensation, Laura E. Niklason, CEO, Director, Beneficial Ownership